Press Releases

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28 at 12pm ET

Panbela to Participate in the 34th Annual Roth Conference

• Panbela management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.
• The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948

Panbela Schedules Conference Call on 3/24/22 to Report 2021 Fourth Quarter Financial Results

Acceptance of SBP-101 Abstract for Poster Presentation at American Association for Cancer Research (AACR)

Panbela Therapeutics, Inc. to Acquire Cancer Prevention Pharmaceuticals, Inc.

• Creates late-stage, diversified pipeline that uses a multi-targeted approach to reset dysregulated biology to address considerable unmet needs
• Combined pipeline extends from pre-clinical to registration studies, with near-term clinical and regulatory milestones
• Acquired lead asset will begin a fully-funded registration trial anticipated to start by year-end

Panbela Initiates a Randomized, Double-Blind, Placebo-Controlled Study (ASPIRE) of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Subjects Previously Untreated for Metastatic Pancreatic Ductal Adenocarcinoma

Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2022 ASCO GI Meeting

Interim data presented in poster reflects median overall survival of 12.0 months, not yet final, and an objective response rate of 48%, both greater than historical rates reported for standard of care

Panbela Announces Positive Preclinical Data Strongly Supporting the Activity of SBP-101 in Ovarian Cancer Cell Lines

Development Program for SBP-101’s Expansion into Ovarian Cancer Expected in 1H 2022

Panbela Announces Acceptance of Abstract for Poster Presentation at American Society of Clinical Oncology Gastrointestinal Cancers Symposium